Richard A. Follows

GSK, Stockley Park
Uxbridge, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges?

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges?

Journal: International forum of allergy & rhinology

Published: March 17, 2026

Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps.

Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps.

Journal: Journal of clinical pharmacology

Published: November 25, 2025

Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven Diseases.

Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven Diseases.

Journal: Clinical pharmacology and therapeutics

Published: July 04, 2025

Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.

Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.

Journal: Lancet (London, England)

Published: November 28, 2024

Usability of mepolizumab single-use prefilled autoinjector for patient self-administration.

Usability of mepolizumab single-use prefilled autoinjector for patient self-administration.

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma

Published: June 29, 2019

Usability of mepolizumab single-use prefilled syringe for patient self-administration.

Usability of mepolizumab single-use prefilled syringe for patient self-administration.

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma

Published: April 25, 2019

Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial.

Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial.

Journal: American journal of respiratory and critical care medicine

Published: November 10, 2015

Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.

Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.

Journal: Current medical research and opinion

Published: September 10, 2013

Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study.

Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study.

Journal: Respiratory research

Published: December 11, 2012

24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids.

24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids.

Journal: The European respiratory journal

Published: February 25, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026